一品红(300723.SZ)：痛风创新药AR882全球Ⅲ期临床试验完成全部受试者入组

Core Viewpoint - Yipinhong Pharmaceutical Group Co., Ltd. has completed the enrollment of all participants in the global Phase III clinical trial for AR882, a novel drug for the treatment of gout and gout stones, developed in collaboration with Arthrosi Therapeutics, Inc. [1] Group 1 - AR882 (generic name: Deuricostat) is a first-class innovative drug that acts as a selective uric acid transporter (URAT1) inhibitor, aimed at normalizing uric acid salt excretion in urine and lowering serum uric acid (sUA) levels [1] - The company indirectly holds a 22.52% stake in Arthrosi [1] - The company, through its wholly-owned subsidiary Guangzhou Ruian Bo Pharmaceutical Technology Co., Ltd., holds 100% of the marketing authorization and all commercialization rights for AR882 in the Chinese region, including mainland China, Hong Kong, Macau, and Taiwan [1]